Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
MTr1 Inhibitor
Trifluoromethyl-tubercidin (TFMT) is an inhibitor of the enzyme 2'-O-ribose methyltransferase 1 (MTr1). This compound effectively disrupts the cap-snatching mechanism utilized by influenza A and B viruses, thereby inhibiting viral replication. TFMT demonstrates notable antiviral activity with minimal toxicity, making it a valuable reagent for studies in virology and antiviral research. -
Influenza Virus Inhibitor
Epigoitrin is a natural alkaloid that exhibits antiviral activity against influenza viruses by inhibiting attachment and replication of the influenza A1 virus FM1 in vitro. This compound enhances the host's resistance to influenza infection, particularly under stress conditions. Additionally, Epigoitrin demonstrates lipid-lowering effects, making it a potential candidate for research in infectious diseases and metabolic health. -
Influenza Virus Inhibitor
2′-Deoxy-2′-fluoroguanosine is a nucleoside analog that serves as a potent inhibitor of influenza viruses, exhibiting an effective concentration (EC90) of less than 0.35 μM against both influenza A and B strains. This compound disrupts the replication process of the influenza virus in the upper respiratory tract, resulting in reduced fever and alleviated nasal inflammation. Its antiviral properties make it a valuable tool for research on influenza virus pathogenesis and therapeutic intervention strategies. -
Influenza Virus Inhibitor
Rupestonic acid is a sesquiterpene that acts as an inhibitor of the influenza virus. This compound demonstrates significant antiviral activity, making it a valuable tool for research focused on influenza virus pathogenesis and therapeutic interventions. Its ability to disrupt viral replication holds potential for the development of novel antiviral strategies. -
Kinase Inhibitor
3-Deoxysappanchalcone is a potent kinase inhibitor that selectively targets MET, EGFR, AKT, mTOR, p38 MAPK, JNK, thrombin, FXa, and influenza virus neuraminidase, modulating key signaling pathways. This compound is known to induce cell cycle arrest, reactive oxygen species (ROS) production, and apoptosis, demonstrating significant biological activities. Its anti-inflammatory, anti-allergic, anticoagulant, and antithrombotic properties make it valuable for research in gefitinib-resistant lung cancer, esophageal squamous cell carcinoma, thrombosis, and influenza virus infections. -
Influenza Virus Inhibitor
Oseltamivir-d3 is a deuterium-labeled derivative of Oseltamivir, which functions as a neuraminidase inhibitor targeting the influenza virus. This compound demonstrates potent antiviral activity against various influenza strains, including A/H3N2, A/H1N2, A/H1N1, and B, with mean IC50 values of 0.67, 0.9, 1.34, and 13 nM, respectively. Oseltamivir-d3 is valuable for research applications focused on influenza virus studies, antiviral drug development, and mechanistic investigations of neuraminidase inhibition. -
CEN Inhibitor
AV5124 is an orally active cap-dependent endonuclease (CEN) inhibitor, functioning as a prodrug of AV5116. It exhibits potent antiviral activity by inhibiting the endonuclease function essential for influenza virus replication. This compound is primarily utilized in research focused on developing antiviral strategies against influenza and understanding viral RNA synthesis mechanisms. -
IAV Inhibitor
VNT-101 is an orally active inhibitor of influenza A virus (IAV) that targets the nucleoprotein (NP) and disrupts NP-NP protein-protein interactions, leading to the destabilization of the viral ribonucleoprotein complex. This compound demonstrates potent antiviral activity across various IAV subtypes, with EC50 values ranging from 4-5 nM in cellular cytopathic effect assays, 4-8 nM in neuraminidase assays, and 21-45 nM in ribonucleoprotein assays. Additionally, VNT-101 shows significant in vivo antiviral efficacy in mice infected with lethal H1N1 virus, making it a valuable tool for studying influenza A infection and potential therapeutic interventions. -
PA endonuclease Inhibitor
L-742001 hydrochloride is an inhibitor of the influenza virus PA endonuclease, specifically targeting the viral RNA polymerase complex. It demonstrates an effective EC90 of 4.3 μM for vRNP activity in HEK293T cells. This compound is valuable for research applications focused on antiviral drug development and understanding viral replication mechanisms. -
H1N1 Inhibitor
CBS1117 is a potent inhibitor of the H1N1 influenza A virus, exhibiting an IC50 of 70 nM. It specifically targets the hemagglutinin (HA) protein, disrupting the viral entry process by interfering with HA-mediated fusion. This compound is valuable for research applications focused on understanding influenza virus entry mechanisms and developing antiviral strategies. -
Cap-dependent Endonuclease Inhibitor
Pixavir marboxilo is a potent orally active cap-dependent endonuclease inhibitor that targets the viral polymerase complex. This compound is primarily utilized in influenza research to investigate viral replication mechanisms and evaluate potential therapeutic strategies. Its high efficacy makes it a valuable tool for studying the pathogenesis of influenza and developing antiviral treatments. -
Influenza A Virus Inhibitor
Influenza A virus-IN-1 is a dihydropyrrolidone derivative that serves as a potent inhibitor of various subtypes of influenza A virus (IAV), exhibiting IC50 values ranging from 3.11 μM to 7.13 μM. This compound effectively inhibits IAV replication and enhances the expression of key antiviral cytokines, including IFN-β, as well as the antiviral protein MxA. Its mechanisms make it a valuable tool for research in antiviral drug development and the study of host immune responses to viral infections. -
NA Inhibitor
7,3',4'-Trihydroxy-3-benzyl-2H-chromene is a reversible noncompetitive neuraminidase (NA) inhibitor with significant antiviral activity. It demonstrates potent inhibitory effects against influenza virus strains, with IC50 values of 34.6 µM for H1N1, 39.5 µM for H3N2, and 50.5 µM for H9N2. This compound, derived from the dried heartwood of Caesalpinia sappan L., serves as a valuable reagent for research applications focusing on influenza virus inhibition and related studies in virology. -
Neuraminidase Inhibitor
AV-5080 is an orally active neuraminidase inhibitor that targets the enzyme involved in the life cycle of influenza viruses. By inhibiting neuraminidase, AV-5080 effectively reduces viral replication and spread, making it a valuable tool in the study of influenza A and B viruses. This compound is suitable for research applications aimed at understanding viral pathogenesis and developing antiviral strategies. -
Influenza Neuraminidase Enzymes Inhibitor
Ganoderic acid TR is an inhibitor of influenza neuraminidase enzymes (NAs), demonstrating significant antiviral activity. It exhibits IC50 values of 10.9 μM and 4.6 μM against H5N1 and H1N1 strains, respectively, making it a promising candidate for further research in influenza treatment. However, Ganoderic acid TR is associated with cytotoxicity and shows limited efficacy against Oseltamivir-resistant H1N1 and influenza B viruses. -
Influenza A Virus Inhibitor
MBX2546 is an inhibitor of the Influenza A virus, specifically targeting H1 and H3 Hemagglutinin with Kd values of 5.3 μM and greater than 100 μM, respectively. This compound demonstrates potential for antiviral research and therapeutic development aimed at combating Influenza A infections. Its selective mechanism of action makes it a valuable tool for studying hemagglutinin-mediated viral entry and host cell interactions. -
Influenza Virus Inhibitor
Amizon is an orally effective antiviral agent targeting the influenza virus. It inhibits viral replication and restricts RNA synthesis, while simultaneously reducing the mRNA expression of pro-inflammatory mediators such as COX-1, COX-2, NF-κB, TGF-β1, IL-1, and IL-6. Additionally, Amizon enhances the secretion and mRNA expression of the anti-inflammatory cytokine IL-10 and exhibits antioxidant properties, inhibiting the oxidative activity of macrophages. This compound is of interest in research focused on influenza and acute respiratory viral infections. -
Cap-dependent Endonuclease Inhibitor
Cap-dependent endonuclease-IN-6 is a potent inhibitor of cap-dependent endonuclease (CEN), a critical enzyme required for the replication of certain viruses, including influenza. This compound exhibits substantial antiviral activity, demonstrating an effective EC50 of 38.21 nM against the influenza virus. It serves as a valuable tool for researchers investigating viral mechanisms and developing antiviral therapies. -
CEN Inhibitor
Cap-dependent endonuclease-IN-20 is an inhibitor of cap-dependent endonuclease (CEN), targeting the viral replication process. It exhibits antiviral activity against the influenza virus A/Hanfang/359/95 (H3N2), with an IC50 of 4.82 μM. This compound is useful for research in virology, particularly in the study of influenza virus mechanisms and the development of antiviral therapeutics. -
Influenza Virus Growth Inhibitor
BMY-27709 is an influenza virus growth inhibitor that primarily targets hemagglutinin proteins. It demonstrates significant antiviral activity with an IC50 value of 3-8 μM against the A/WSN/33 strain. BMY-27709 effectively inhibits the growth of H1 and H2 subtype viruses early in the infection process, making it a valuable tool for research into influenza virus pathogenesis and therapeutic development. However, it does not inhibit H3 subtype viruses or influenza B/Lee/40 strains. -
CEN Inhibitor
Cap-dependent endonuclease-IN-9 is a selective inhibitor of cap-dependent endonuclease (CEN), demonstrating significant efficacy against influenza viruses. This compound exhibits low cytotoxicity and favorable pharmacokinetic and pharmacodynamic properties in vivo. Cap-dependent endonuclease-IN-9 effectively inhibits the RNA polymerase activity of A viruses, making it a valuable tool for research in antiviral therapeutics and molecular biology studies. -
Endonuclease Inhibitor
Flutimide is a selective endonuclease inhibitor that targets the influenza virus. Demonstrating an IC50 value of 3 μM, Flutimide exhibits significant antiviral activity in cell culture assays. This compound is valuable for research focused on acute contagious respiratory diseases, particularly influenza, and can aid in the investigation of therapeutic strategies against viral infections. -
Influenza A Virus Inhibitor
3-epi-Dihydroscandenolide is a sesquiterpene lactone that serves as an inhibitor of influenza A virus. Isolated from the dried aerial parts of Mikania micrantha, this compound effectively inhibits the cytopathic effects induced by the virus. 3-epi-Dihydroscandenolide is valuable for research applications focused on influenza A and may aid in the development of antiviral strategies. -
A/M2 Inhibitor
3-Azaspiro[5.5]undecane hydrochloride is an inhibitor of the wild-type influenza A virus M2 ion channel. It demonstrates potent biological activity with an IC50 value of 1 μM, making it a valuable tool for studying influenza virus function and host-pathogen interactions. This compound is applicable in viral research and can aid in the development of antiviral strategies targeting M2. -
Hemagglutinin Inhibitor
Influenza virus-IN-5 is a potent inhibitor of influenza virus hemagglutinin (HA), demonstrating an EC50 of 1 nM against the influenza A/H3N2 strain. This compound is valuable for research applications focused on viral entry and infection mechanisms. Its high selectivity and efficacy make it an important tool for studying influenza virus pathogenesis and developing antiviral strategies. -
CEN Inhibitor
Cap-dependent endonuclease-IN-26 is a selective inhibitor of cap-dependent endonuclease (CEN), exhibiting an IC50 of 286 nM. This compound demonstrates significant antiviral activity against various strains of influenza A and B, making it a valuable tool for research in antiviral therapy and mechanisms of viral replication. Its use may advance the understanding of CEN's role in viral RNA processing and contribute to the development of new antiviral strategies. -
CEN Inhibitor
Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN), primarily targeting influenza A virus. This compound demonstrates significant inhibitory activity, making it a valuable tool for studying the mechanisms of influenza virus infection. Researchers can utilize Cap-dependent endonuclease-IN-13 to explore viral replication pathways and evaluate potential therapeutic interventions. -
PAN Endonuclease Inhibitor
PAN endonuclease-IN-1 is a potent inhibitor of PAN endonuclease, showing Kd values of 277 μM, 384 μM, and 328 μM for wild-type, I38T, and E23K variants, respectively. Targeting the RNA-dependent RNA polymerase acidic N-terminal endonuclease, this compound plays a critical role in disrupting influenza viral replication. It is a valuable tool for studying antiviral strategies and the effects of PAN endonuclease inhibition on influenza virus biology. -
Influenza Virus Inhibitor
Influenza virus-IN-2 is a potent inhibitor of the influenza virus, demonstrating significant antiviral activity with an EC50 of 2.58 µM and a cytotoxicity threshold of CC50 at 150.85 µM. This compound exhibits concentration-dependent inhibition of PAN endonuclease, with an EC50 of 489.39 nM. Influenza virus-IN-2 is effective against influenza A virus, making it a valuable tool for research focused on antiviral drug development and the mechanisms of influenza virus replication. -
Neuraminidase Inhibitor
Ganoderic acid T-N is a triterpenoid compound that functions as a neuraminidase inhibitor, specifically targeting H5N1 and H1N1 influenza strains with IC50 values of 2.7 μM and 42 μM, respectively. In addition to its antiviral properties, Ganoderic acid T-N demonstrates cytotoxic effects against MCF7 cancer cells, exhibiting a CC50 value of 24.4 μM. This compound is relevant for research applications in virology and cancer biology, providing insights into influenza pathogenesis and potential therapeutic strategies. -
Influenza Viru Inhibitor
Tirfipiravir is a nucleoside analog with antiviral properties, primarily targeting influenza viruses. This compound exhibits potent activity against viral replication by inhibiting RNA polymerase, making it a valuable tool for research on viral infections. Tirfipiravir is particularly applicable in studies focusing on the mechanisms of antiviral resistance and developing therapeutic strategies against influenza. -
Neuraminidase Inhibitor
Influenza A virus-IN-4 is a potent neuraminidase inhibitor with significant antiviral activity against influenza A viruses. As an Oseltamivir derivative, it effectively impedes viral replication by blocking the enzymatic function of neuraminidase, thereby preventing the release of new viral particles. This compound is valuable for research focused on influenza virology and therapeutic intervention strategies. -
CEN Inhibitor
Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent endonuclease (CEN), targeting the enzymatic activity crucial for the replication of various viruses, including influenza. This compound demonstrates a strong inhibitory effect on RNA polymerase activity in A viruses, making it a valuable tool for virology research. Notably, Cap-dependent endonuclease-IN-2 exhibits lower cytotoxicity and favorable pharmacokinetic properties in vivo, supporting its potential as an effective antiviral agent for further investigation. -
Cap-dependent Endonuclease Inhibitor
Influenza virus-IN-7 is a potent cap-dependent endonuclease inhibitor designed for research into influenza viral infections. This compound exhibits oral bioavailability and can effectively modulate the viral lifecycle by hindering the endonuclease activity essential for viral RNA processing. Its application extends to studies focusing on influenza pathogenesis and the development of antiviral therapies. -
CEN Inhibitor
Cap-dependent endonuclease-IN-5 is a selective inhibitor of cap-dependent endonuclease (CEN), a crucial enzyme in the lifecycle of the influenza virus. This compound demonstrates significant antiviral activity against influenza while exhibiting lower cytotoxicity compared to existing treatments. Additionally, Cap-dependent endonuclease-IN-5 shows improved pharmacokinetic and pharmacodynamic properties in vivo, making it a valuable tool for research on CEN-targeted antiviral therapies. -
CEN Inhibitor
Cap-dependent endonuclease-IN-16 is a potent inhibitor of cap-dependent endonuclease (CEN). This pyridone polycyclic derivative is designed for research applications focusing on influenza, specifically targeting the viral replication process. Its inhibitory effects on CEN make it a valuable tool for studying the mechanisms of RNA transcription and development of antiviral strategies. -
CEN Inhibitor
Cap-dependent endonuclease-IN-21 is a potent inhibitor of cap-dependent endonuclease (CEN), crucial for the replication of influenza viruses. This compound specifically targets influenza A, demonstrating significant antiviral activity. It serves as a valuable tool for research focused on understanding influenza virus infection and developing therapeutic strategies against this pathogen. -
Neuraminidase (NA) Inhibitor
Neuraminidase-IN-10 is a highly potent inhibitor of neuraminidase (NA), exhibiting significant anti-influenza activity. It demonstrates inhibitory effects against H1N1, H5N1, and H5N8 strains with IC50 values of 2.6 nM, 5.1 nM, and 1.65 nM, respectively. This compound is valuable for research applications focusing on viral pathogenesis and therapeutic development for influenza infections. -
RSV Inhibitor
RSV-IN-3 is a dual inhibitor targeting respiratory syncytial virus (RSV) and influenza virus A (IAV). It demonstrates significant anti-RSV activity with an EC50 value of 32.70 μM. RSV-IN-3 can be utilized in research focused on viral pathogenesis and the development of antiviral therapeutics for respiratory viral infections. -
CEN Inhibitor
Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent endonuclease (CEN), which plays a critical role in viral RNA synthesis. This compound effectively inhibits multiple strains of the influenza virus while exhibiting lower cytotoxicity and favorable in vivo pharmacokinetic and pharmacodynamic profiles. Additionally, Cap-dependent endonuclease-IN-10 demonstrates enhanced hepatic microsomal stability, making it valuable for research applications focused on viral infections, including influenza A, B, and C. -
HA Inhibitor
RO5487624 is an orally active hemagglutinin (HA) inhibitor that targets the influenza H1N1 virus. It functions by disrupting HA conformational changes necessary for viral fusion in acidic environments, effectively preventing virus entry into host cells. In preclinical studies, RO5487624 has demonstrated protective effects in mice challenged with lethal doses of the influenza H1N1 virus, highlighting its potential applications in antiviral research and therapeutic development. -
RSV/IAV Inhibitor
RSV/IAV-IN-3 is a dual inhibitor targeting both respiratory syncytial virus (RSV) and influenza A virus (IAV) with reported EC50 values of 2.92 µM and 1.90 µM, respectively. This compound exhibits significant antiviral activity against H1N1 and H3N2 strains, achieving EC50 values of 3.25 µM and 1.50 µM in MDCK cells. Notably, RSV/IAV-IN-3 inhibits IAV infectivity and RNA-dependent RNA polymerase (RdRp) activity while effectively suppressing viral replication at the post-entry stage. Its influence on luciferase activity further emphasizes its potential in antiviral research applications. -
CEN Inhibitor
Cap-dependent endonuclease-IN-14 is a selective inhibitor of cap-dependent endonuclease (CEN), a key enzyme involved in the replication of influenza viruses. By disrupting the function of CEN, this compound effectively inhibits viral replication, making it a valuable tool for studying influenza virus infections. Its application extends to virology research focused on antiviral drug development and understanding the mechanisms of influenza pathogeneses. -
Neuraminidase Inhibitor
Neuraminidase-IN-8 is a potent inhibitor of neuraminidase, demonstrating an IC50 of 0.027 µM. This compound exhibits significant anti-influenza activity, making it a valuable tool for research into antiviral therapies targeting influenza virus replication and spread. Its effectiveness in inhibiting neuraminidase enzymes supports its use in studies aimed at developing new strategies for influenza treatment. -
Neuraminidase Inhibitor
Neuraminidase-IN-11 is a highly potent and selective inhibitor of neuraminidase with IC50 values of 4.7 nM, 8.46 nM, and 1.5 nM against H1N1, H5N1, and H5N8 neuraminidases, respectively. This compound plays a crucial role in the study of viral pathogenesis and therapeutic interventions for influenza. Its selective inhibition of neuraminidase makes it an important tool for understanding antiviral drug efficacy and the modulation of viral replication dynamics. -
Influenza Virus Inhibitor
Antiviral agent 35 is a potent inhibitor of influenza virus replication, functioning effectively during the early stages of the viral life cycle. It reduces reactive oxygen species (ROS) accumulation, as well as autophagy and apoptosis induced by the virus, while also mitigating the inflammatory response mediated by the RIG-1 pathway in mouse models of pulmonary infection. This compound exhibits low cytotoxicity, with a CC50 greater than 800 μM in MDCK cells, and demonstrates anti-H1N1 activity with an EC50 of 2.28 μM, making it a valuable tool for research on influenza virus inhibition. -
Influenza A Virus Inhibitor
Influenza A virus-IN-18 (Compound C2e) is an orally active inhibitor specifically targeting the Influenza A virus. It demonstrates significant antiviral activity, with an IC50 value of 2.5 μM against PR8/H1N1 and 6.42 μM against H3N2 strains. Influenza A virus-IN-18 exhibits a high affinity for the H1N1/PR8 hemagglutinin protein, with a KD of 0.25 μM. This compound is valuable for research in Influenza A virus infection and therapeutic development. -
H5N1 Inhibitor
Yadanziolide B is a natural quassinoid that functions as an inhibitor of H5N1 neuraminidase, an essential enzyme for the viral life cycle. Its inhibitory activity makes it a valuable candidate for research applications focusing on antiviral therapies targeting H5N1 influenza. Studies exploring its properties may contribute to the development of effective treatments for influenza virus infections. -
RdRP Inhibitor
RdRP-IN-5 is a potent inhibitor of influenza virus RNA-dependent RNA polymerase (RdRP). This compound exhibits significant antiviral activity, making it a valuable tool for the study of influenza virus replication and pathogenesis. Researchers can utilize RdRP-IN-5 to investigate therapeutic strategies targeting RNA polymerase in viral infections. -
Influenza Viru Inhibitor
NSC-65847 is a dual inhibitor that targets both viral neuraminidase and Streptococcus pneumoniae neuraminidase, disrupting essential enzymatic functions. Its unique mechanism of action impedes the replication and spread of Influenza viruses, making it a valuable tool in antiviral research. Research applications include studying viral infections and developing therapeutic interventions for influenza and associated bacterial co-infections.
